

Fig 1




Fig. 4





Fig. 3



202020 75872001







Fig 5

2013-03-20



Months after Radical Prostatectomy

Fig 6 A

2007-03-20 14:23:00





Fig 6B



Months after Radical Prostatectomy

Fig 7





Fig 8

2020-1981/001



Fig




Figure10




Figure 11

Preoperative Prediction of PSA-Progression Free Survival in the 468 Prostatectomy Patients

Multivariate Cox Proportional Hazards Analysis

Factor	p-value	Hazards Ratio	95% CI
Preop PSA	0.005	1.761	1.181-2.625
Ex Gleason Sum	<0.001	2.896	1.630-5.145
Clinical Stage	0.879	1.039	0.633-1.707
Preop TGF- β_1	<0.001	1.170	1.078-1.270
Preop IL-6	0.077	1.038	0.996-1.082
Preop IL-6 sR	0.038	1.215	1.011-1.461

Comparison of Predictive Value of Pre-op versus Post-op Levels for PSA-Progression Free Survival in 468 Prostatectomy Patients

Multivariate Cox Proportional Hazards Analyses

(All models included preop PSA, ECE, Gleason, SVI, SM)

Factor	p-value	Hazards Ratio	95% CI
Preop TGF- β_1	0.400	1.074	0.909-1.269
Postop TGF- β_1	0.001	1.285	1.112-1.486
Preop IL-6	0.042	1.249	1.008-1.546
Postop IL-6	0.297	1.132	0.897-1.429
Preop IL-6 sR	0.020	1.174	1.011-1.241
Postop IL-6 sR	0.224	0.966	0.915-1.021